Acute, single, intravenous doses of XXXX : an evaluation of safety, tolerance, and hemodynamic effects.

@entity1 @entity998 @entity5354 @entity3297 @entity7306
@entity5354 is a new antiarrhythmic agent with predominant @entity3297 properties. The safety, tolerance, and adverse effects of incremental single intravenous doses of this agent were investigated. A total of 28 @entity1 received incremental doses of 0.25 mg/kg (four @entity1 ), 0.5 mg/kg (five @entity1 ), 0.75 mg/kg (seven @entity1 ), 1.0 mg/kg (six @entity1 ), or 1.2 mg/kg (six @entity1 ) @entity5354 . Another six @entity1 received 2.0 mg/kg @entity7306 . Left ventricular function by radionuclide ventriculography and plasma @entity5354 levels were measured at frequent intervals. In the @entity1 who received 1.0 mg/kg and 1.2 mg/kg @entity5354 or @entity1 who received 2.0 mg/kg @entity7306 , right and @entity998 were measured with a Swan-Ganz catheter. At low-dose @entity5354 (0.25 to 0.75 mg/kg) there was a modest drop in ejection fraction (60% +/- 7% to 53% +/- 7%). With the higher doses of @entity5354 (1.0 or 1.2 mg/kg) there was a more profound fall in ejection fraction (69% +/- 8% to 49% +/- 8%) that persisted for approximately 2 hours. This was associated with a rise in end diastolic volume index (74 +/- 24 to 85 +/- 27 ml/m2) and end systolic volume index (29 +/- 15 to 43 +/- 18 ml/m2) and a fall in cardiac index (2.65 +/- 0.62 to 2.14 +/- 0.24 L/min/m2).(ABSTRACT TRUNCATED AT 250 WORDS)
